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ABSTRACT
Objective To determine the incidence of retinitis 
pigmentosa (RP) in South Korea.
Design Nationwide, population-based retrospective study.
Setting Census population of South Korea
Participants This study involved the entire population of 
South Korea (n=47 990 761). Patients confirmed as having 
RP by an ophthalmologist from 1 January 2011 to 31 
December 2014 were included.
Primary outcome measure The average incidence of 
RP during the 4-year study period was estimated using 
population data from the 2010 Korean census.
Results A total of 3144 (1567 men and 1577 women) 
patients confirmed as having RP were identified. The 
average incidence of RP was 1.64 cases/100 000 
person-years (95% CI 1.58 to 1.70). The incidence of RP 
distribution skewed to the left across age groups, with 
one smaller peak observed in the 20–24-year-old age 
group (1.24 cases/100 000 person-years) and a larger 
peak observed in the 65–69-year-old age group (3.26 
cases/100 000 person-years). The overall incidence was 
similar in men and women (1.64 cases/100 000 person-
years (95% CI 1.56 to 1.73) for men; 1.63 cases/100 000 
person-years (95% CI 1.55 to 1.72) for women).
Conclusions Our study’s estimates of the nationwide 
population-based incidence of RP in an Asian population 
will help advance the understanding of the disease onset 
and allow healthcare systems to plan accordingly.
INTRODUCTION
Retinitis pigmentosa (RP) includes a group 
of heterogeneous hereditary retinal degener-
ation disorders caused by the progressive loss 
of photoreceptor cells.1 2 It is characterised 
by widespread retinal degeneration and is an 
important and leading cause of blindness.3 
However, there is a paucity of data based on 
large, well-defined populations regarding the 
epidemiological characteristics of RP. Ideally, 
a study evaluating the epidemiology of RP 
should be based on population data rather 
than on data obtained from a tertiary referral 
centre to avoid the effects of a referral bias. To 
the best of our knowledge, only a few recent 
studies have collected data from a general 
population and calculated the incidence of 
RP. The incidence of RP was reported in only 
two previous studies conducted in Denmark 
(0.79 cases/100 000 person-years)4 and in 
the state of Maine in the USA (6 cases/100 
000 person-years).5 Despite recent large-scale 
health-related studies,6–8 there are no nation-
wide RP-related epidemiological studies. In 
general, incidence estimates provide more 
information than prevalence estimates with 
regard to a disease’s characteristics and to 
help healthcare systems plan accordingly.
South Korea has a mandatory universal 
health insurance system covering the entire 
population of 48 million people; therefore, 
the medical claims database includes all 
healthcare use in South Korea. In addition, 
the Korean government initiated a regis-
tration programme for rare and intractable 
disorders, such as RP, in 2007. Patients with RP 
registered in this programme are eligible for 
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Strengths and limitations of this study
 ► In this retrospective cohort study of registry data on 
retinitis pigmentosa (RP) for the entire South Korean 
population, the incidence of RP was found to be 1.64 
cases per 1 00 000 person-years.
 ► This study is unique because it included the largest 
population ever studied in terms of this rare disease, 
and it represents the first investigation of the 
nationwide incidence of RP in an Asian country.
 ► Only a few recent studies have collected data for 
a general population and calculated the incidence 
of RP. There are no nationwide RP-related 
epidemiological studies.
 ► A lack of clinical information, including family 
pedigree, visual acuity, visual field and genetic 
analysis, is an inherent limitation of the present 
claims database study.
 ► Although not ideal, our approach was cost-effective 
for identifying patients with RP and calculating 
the incidence of RP in the entire South Korean 
population.
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up to a 90% co-payment reduction after the diagnosis has 
been confirmed by an ophthalmologist using the Korean 
National Health Insurance Service (KNHIS) diagnostic 
criteria based on an electrophysiological examination. 
Our aim was to use this database to conduct a nationwide, 
population-based study to determine the incidence of RP 
in South Korea.
SUBJECTS AND METHODS
Statement of ethics
This retrospective nationwide cohort study was reviewed 
and approved by the Institutional Review Board of the 
National Health Insurance Service Ilsan Hospital, Gyeo-
nggi-do, Korea. This study adhered to the tenets of the 
Declaration of Helsinki, and written informed consent 
was waived.
RP registration in South Korea and its definition
All Korean residents are obligated to enrol in the KNHIS. 
Claims are accompanied by data regarding diagnostic 
codes, procedures, prescription drugs, personal infor-
mation, and information about the hospital. No patient 
healthcare records are duplicated because all Korean 
residents receive a unique identification number at birth. 
Furthermore, the KNHIS uses the Korean Classification 
of Diseases, which is a system similar to the International 
Classification of Diseases. In 2007, the National Health 
Insurance Service initiated a co-payment reduction of up 
to 90% for patients suffering from 138 rare and intractable 
disorders, including RP. Patients with RP who registered 
in the programme were eligible for co-payment reduction 
after receiving a confirmed diagnosis by an ophthalmol-
ogist based on the National Health Insurance Service 
diagnostic criteria. The National Health Insurance Service 
diagnostic criteria for RP require: (1) ophthalmoscopic 
abnormalities of the retina on a dilated fundus examina-
tion; and (2) electroretinographic changes confirming 
the presence of RP-related photoreceptor damage. All 
submissions for co-payment reduction registration were 
reviewed and confirmed by the Health Insurance Review 
Agency. Patients must reapply for co-payment reduction 
registration every 5 years after the initial registration to 
maintain the co-payment reduction. After registration, all 
RP-related claims contain the RP registration code (V209) 
in addition to the diagnostic code for RP (Korean Classi-
fication of Diseases H3551). Patients who filed claims for 
RP (V209, H3551) from January 2011 to December 2014 
with the KNHIS were included in this study. We excluded 
patients with chronic RP registered between 1 January 
2007 and 31 December 2010, because RP (H3551) and 
Stargardt disease (H3558) shared the same registration 
code (V209) and did not have a Korean Classification of 
Diseases diagnostic code in the KNHIS database during 
this time. Finally, we obtained RP registration data from 
the national health claim database between 2007 and 
2014, and calculated the incidence of RP between 2011 
and 2014.
Statistical analysis
The incident time was defined as the registration date of 
a rare and intractable disorder diagnosed as RP. Annual 
population data were obtained from the Population and 
Housing Census conducted in 2010 and available from 
the Korean Statistical Information Service (http:// kosis. 
kr). Detailed demographic characteristics of the South 
Korean population are listed in table 1. The person-time 
incidence rates for 2011–2014 were calculated as the 
number of people who developed RP divided by the total 
person-time at risk during the study period. Therefore, in 
this analysis, person-years were counted after the incident 
time. The incidence per 100 000 person-years, based on the 
2010 census, was estimated using the Poisson distribution. 
In our explorative analysis (see online Supplementary 
appendix) the total number of RP cases from 2007 to 
2014 was estimated at 7424. Prevalent cases of RP were 
not excluded from the population at risk because the 
denominator (total Korean person-time at risk) was large 
enough to not be affected in terms of incidence. The total 
person-time at risk was assumed as the total population 
(census in 2010, n=47 990 761, table 1) over 4 years from 
2011 to 2014 (population multiplied by four). The annual 
incidence from 2011 to 2014 and overall incidence were 
estimated with 95% confidence intervals; additionally, 
the age-specific and sex-specific incidence rates were 
estimated, and the age-specific population for each year 
was approximated based on the 2010 census population. 
The male-to-female ratio for the RP incidence rate was 
also estimated. A significance level of 0.05 was selected. 
All analyses were conducted using Stata/MP, version 14.0 
(StataCorp, College Station, TX, USA).
RESULTS
The total number of incident cases of RP from 2011 to 2014 
in South Korea was 3144, including 1567 men (49.9%) 
and 1577 women (50.1%). The incidence of RP during 
the study period was 1.64 cases/100 000 person-years. In 
men the incidence was 1.64 cases/100 000 person-years, 
and in women it was 1.63 cases/100 000 person-years. The 
peak incidence in the total population was observed in 
the 65–69-year-old age group (3.26 cases/100 000 person-
years; men 3.00 cases/100 000 person-years; women 
3.86 cases/100 000 person-years) (table 1 and figure 1). 
Although there was some variation between the different 
periods and age groups, the overall incidences in men 
and women were similar (male-to-female ratio=1.01, 
p=0.80). The incidence of RP distribution was negatively 
skewed (skewed to the left) across age groups, with one 
smaller peak observed in 20–24-year-olds (1.24 cases/100 
000 person-years). The incidence was slightly decreased 
in the 25–29-year-old age group (1.07 cases/100 000 
person-years), and the maximum incidence was seen in 
the 65–69-year-old age group (3.26 cases/100 000 person-
years) (figure 1). The incidence for women steadily 
increased with age, reaching a maximum level in the 
65–69-year-old age group, and then it gradually decreased 
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after age 69. There was a unique peak in incidence for 
men around 20 years of age (figure 1).
There were 851 (27.1%), 708 (22.5%), 728 (23.2%), 
and 857 (27.3%) incident cases in 2011, 2012, 2013, 
and 2014, respectively. There was little difference in the 
annual number of newly diagnosed patients with RP from 
2011 to 2014. The annual incidence of RP was slightly 
higher in 2011 and 2014, and slightly lower in 2012 
and 2013 (1.77 cases/100 000 population in 2011, 1.48 
cases/100 000 population in 2012, 1.52 cases/100 000 
population in 2013, and 1.79 cases/100 000 population 
in 2014) (table 2).
DISCUSSION
In the present study, using the KNHIS database between 
2011 and 2014, we found a nationwide, population-based, 
estimated RP incidence of 1.64 cases/100 000 person-
years. This study involved a survey of the entire South 
Korean population using reliable data based on an 
ophthalmologist-confirmed RP registration.
RP is not an acute symptomatic disease like retinal 
vascular occlusion. The most common initial symptom of 
RP, night blindness, has an insidious onset and may go 
unperceived for many years. Patients often become cogni-
sant of RP incidentally. Therefore, previous studies from 
Japan noted the disease onset as the time of a diagnosis of 
RP by an ophthalmologist.9 Another study from Denmark 
discussed possible recall bias, and patients were classified 
as possible, probable, or certain according to the pres-
ence of specified diagnostic criteria and confirmatory 
electroretinographic changes. RP is very rare; therefore, 
it is impossible to estimate the incidence without a large 
cohort of subjects, such as that provided by nationwide 
data. However, it is practically impossible to perform 
ophthalmological examinations of the entire population 
to diagnose a rare intractable disease such as RP. Our 
study design was based on the ophthalmologist-confirmed 
RP registry, and it demonstrated a high specificity for the 
Figure 1 Average incidence of retinitis pigmentosa (RP). 
Incidence per 100 000 person-years of RP in the South 
Korean population according to age groups from 2011 to 
2014.
Table 2 Demographic characteristics of South Koreans and the annual incidence of retinitis pigmentosa per 100 000 person-
years in the South Korean population (2011–2014)
2011 2012 2013 2014
Age (years) Total Men Women Total Men Women Total Men Women Total Men Women
0–4 0.05 0.09 0.00 0.05 0.09 0.00 0.05 0.09 0.00 0.05 0.09 0.00
5–9 0.21 0.40 0.00 0.33 0.40 0.26 0.17 0.08 0.26 0.17 0.24 0.09
10–14 0.13 0.24 0.00 0.25 0.18 0.33 0.25 0.36 0.13 0.25 0.18 0.33
15–19 1.16 1.75 0.50 0.84 1.15 0.50 0.73 0.88 0.56 0.84 1.26 0.37
20–24 1.44 1.66 1.19 0.88 1.11 0.63 1.15 1.48 0.77 1.47 1.91 0.98
25–29 1.47 1.61 1.32 0.88 0.94 0.81 0.93 1.22 0.63 1.02 0.89 1.15
30–34 1.41 1.23 1.59 1.19 1.34 1.04 1.49 1.71 1.26 1.57 1.71 1.42
35–39 1.68 1.84 1.52 1.22 1.26 1.18 1.59 1.70 1.47 1.34 1.46 1.23
40–44 1.65 1.54 1.75 1.94 2.17 1.70 1.69 1.79 1.60 2.15 2.32 1.99
45–49 1.77 1.71 1.82 1.69 1.91 1.48 1.72 1.37 2.07 2.28 2.25 2.32
50–54 3.37 3.07 3.66 2.47 2.65 2.30 2.24 2.28 2.20 2.58 2.81 2.36
55–59 3.04 3.01 3.06 2.42 2.35 2.49 2.82 2.79 2.85 3.54 2.87 4.20
60–64 3.39 2.93 3.82 3.30 3.41 3.20 3.07 2.74 3.38 3.21 2.93 3.47
65–69 3.92 2.76 4.90 2.70 2.28 3.06 2.98 1.92 3.88 3.42 3.24 3.58
70–74 3.00 2.97 3.02 2.68 3.27 2.24 2.81 2.08 3.36 2.87 2.38 3.25
75–79 2.21 2.92 1.78 1.75 2.19 1.48 1.94 2.43 1.63 4.06 4.38 3.86
80–84 2.02 1.08 2.44 2.35 0.54 3.17 2.02 3.23 1.47 3.02 2.15 3.42
≥85 1.09 2.11 0.74 1.09 2.11 0.74 0.27 0.00 0.37 1.09 2.11 0.74
Total 1.77 1.74 1.81 1.48 1.56 1.40 1.52 1.50 1.53 1.79 1.77 1.80
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diagnosis. Although not ideal, our approach was cost-ef-
fective for identifying patients with RP and calculating the 
incidence of RP in the entire South Korean population. 
Studying a large cohort, such as the entire South Korean 
population, and having a 4-year study period may provide 
stability to the heterogeneous detection rate seen with 
this insidious disease. These properties limit the chance 
probabilities that may occur with studies of smaller local-
ised populations or tertiary hospital-based populations. 
Studies regarding the incidence of other rare intractable 
diseases, such as exudative age-related macular degenera-
tion7 and Moyamoya disease,8 using the same registration 
database have been previously reported.
Using the South Korean national claims database 
from 2011 to 2014, which includes the RP registration 
programme, we estimated the incidence rate of RP as 
1.64 cases/100 000 person-years (95% CI 1.58 to 1.70). 
To the best of our knowledge, only two previous studies 
have estimated the incidence of RP based on an adequate 
number of patients with RP. A well-defined local area study 
conducted in the 1980s in the US state of Maine estimated 
that the incidence of RP was 6 cases/100 000 person-
years.5 Another important previous study regarding the 
epidemiology of RP, performed in Denmark in the 2000s, 
reported an average incidence of 0.79 cases/100 000 
person-years from 1990 to 1997.4 The incidence of RP in 
South Korea found in the present study is lower than that 
seen in Maine and greater than that seen in Denmark.
Information regarding the age of disease onset is mean-
ingful in genetic counselling, and a previous study from 
Japan described an age at onset curve for RP based on 370 
patients with RP.9 The age at onset, defined as the age of 
diagnosis, gradually increased with age until age 65 and 
subsequently remained steady after the age of 65.9 In the 
Danish RP study,4 the incidence of RP also increased until 
age 60–64 years, and then it decreased in people older 
than 65 years, similar to the trend seen in the present 
study (figure 1). In terms of sex, the Danish cohorts with 
RP showed a nearly equal increase in the annual inci-
dence between men and women from 1990 to 1997.4 The 
present study showed similar trends; the overall male-to-
female ratio was 1.01 (p=0.86) and the annual incidence 
of RP was similar for men and women during the 4-year 
study period (table 2). However, the estimated age-spe-
cific incidence of newly diagnosed patients was nearly 
double in male patients compared with female patients 
in the 20–24-year-old age group (men 1.54 cases/100 
000 population, women 0.89 cases/100 000 population) 
(table 1). In addition, the incidence of RP was greater in 
women than in men aged 50–65 years. In the Danish RP 
study, the age at onset was much higher in male patients 
than in female patients aged 6–18 years.4 Our results 
also show that the onset may be earlier in male individ-
uals than in female individuals. However, the specifics 
of military service in South Korea should also be consid-
ered. The higher incidence of RP in men in their 20s 
entering mandatory military service in South Korea may 
be because they are more frequently subjected to physical 
examinations related to potential exemption from the 
military service.
To the best of our knowledge, this is the largest popu-
lation ever studied for this rare disease based on an 
ophthalmologist-confirmed diagnosis. It is also the first 
study to investigate the nationwide incidence of RP in an 
Asian country.
However, this study has several limitations. First, as 
aforementioned, it is difficult to define the exact time 
of onset of RP, and we arbitrarily defined the time of 
occurrence of RP as the time when the patients were diag-
nosed as having RP by an ophthalmologist, as in previous 
studies.4 9 Second, we may have underestimated the inci-
dence rates of RP. We identified patients with RP using 
healthcare claims but could not include asymptomatic 
patients or patients who did not use healthcare services. 
Since there is no cure for RP yet, some patients may not 
want to register, even though they have been diagnosed 
as having RP. However, it is reasonable to assume that 
people with symptomatic RP are likely to use healthcare 
services at some time in the course of the disease. The 
universal health insurance coverage and co-payment 
reduction with the registration programme for this rare 
and intractable disorder may also help to encourage 
healthcare use among patients with RP. Moreover, 
healthcare accessibility in South Korea is very high. The 
estimated incidence of newly diagnosed patients showed 
a consistent annual pattern, and the relatively long study 
period, including 4 years of data, may offset this limita-
tion. Third, the diagnosis of RP was defined based on 
the healthcare registration and a Korean Classification of 
Diseases code, which may be inaccurate compared with 
a diagnosis obtained from a medical record. However, 
patients with RP in this study had their RP diagnoses 
confirmed by ophthalmologists based on the National 
Health Insurance Service diagnostic criteria, including 
electroretinography, which provides a test result that is 
considered a confirmatory criterion.4 In addition, the 
eligibility of submitted registrations was reviewed compre-
hensively by the Health Insurance Review Agency. Fourth, 
a lack of clinical information, including family pedigree, 
visual acuity, visual field and genetic analysis, is another 
inherent limitation of the present claims database study. 
Fifth, we only targeted subjects in South Korea. There-
fore, this result cannot be directly compared with those 
of other ethnic groups. Lastly, we did not report the 
prevalence of RP because of the characteristics of the 
South Korean national claims database. The analysis of 
prevalence for RP was impossible with the Korean Classi-
fication of Disease, sixth edition (Korean Classification of 
Diseases-6) system, in which RP, Stargardt disease, vitelli-
form retinal dystrophy and other unspecified hereditary 
retinal dystrophies were similarly categorised as heredi-
tary retinal dystrophy (H35.5). In this study, we excluded 
subjects with RP registered before 31 December 2010 
because it was difficult to distinguish between these 
diseases in the KNHIS database. In our explorative anal-
ysis, only 109 incident cases of Stargardt disease were 
6 Rim TH, et al. BMJ Open 2017;7:e015531. doi:10.1136/bmjopen-2016-015531
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observed from 2011 to 2014, a relatively small number 
compared with the 3144 cases of RP. Therefore, we have 
presented the period prevalence of presumed RP in the 
Supplementary appendix as 15.47 cases/100 000 persons 
(~1/6500), a value consistent with previous reports 
(12–26 cases/100 000 persons or 1/3800–8300)5 10–12 and 
slightly lower than that found in Danish cohorts with RP 
(22.4 cases/100 000 persons).4
In conclusion, we estimated the nationwide incidence 
of newly diagnosed patients with RP in South Korea using 
a database that included the entire national population 
during the 4-year period from 2011 to 2014. The estimated 
population-based incidence rate of RP for all ages was 
1.64 cases/100 000 persons-years, and there was generally 
no difference in the rates between men and women. Our 
study should be helpful in assessing the RP-related socio-
economic burden and in planning accordingly within the 
healthcare system.
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